YINCHUAN, China, May 20, 2026 /PRNewswire/ — Electrical installation work at the newly built Xiling 750kV Substation was successfully completed on May 18, 2026, following the installation of the final bushing for the 750kV gas-insulated switchgear (GIS). State Grid Ningxia Electric Power Co., Ltd. Material Company provided full-process, high-efficiency material support throughout the project, achieving zero delays, zero errors and zero quality issues. Its robust supply guarantee and full-cycle services laid a solid foundation for the project’s on-time, high-quality completion, strongly advancing the construction of a new-type power system in Ningxia.

As a pivotal hub project for optimizing the power grid structure, enhancing power supply capacity and facilitating new energy consumption, the Xiling 750kV Substation Project features high construction standards, tight schedules, a wide range of equipment and stringent technical accuracy requirements.

Since the project’s launch, State Grid Ningxia Electric Power Co., Ltd. Material Company has implemented a dedicated project manager system, full-process closed-loop management and cross-departmental collaboration mechanisms. State Grid Ningxia Electric Power Co., Ltd. Material Company has closely coordinated with project construction, supervision and design parties to accurately sort out material demand lists, technical standards, delivery schedules and installation sequences, and formulated reverse construction plans.

State Grid Ningxia Electric Power Co., Ltd. Material Company has built a comprehensive support chain covering demand docking, production control, quality supervision, logistics scheduling, on-site acceptance and after-sales service. Adhering to the concept that “supply guarantee goes beyond delivery, and services run through the entire process”, State Grid Ningxia Electric Power Co., Ltd. Material Company stationed on-site personnel at the construction site to respond to on-site needs promptly.

Through telephone, WeChat and official work letters, State Grid Ningxia Electric Power Co., Ltd. Material Company coordinated with 32 manufacturers and deployed more than 110 on-site service personnel to quickly resolve technical and material matching issues. State Grid Ningxia Electric Power Co., Ltd. Material Company also proactively collaborated with all parties to optimize installation connection processes, eliminating construction obstacles through efficient coordination and attentive services, and safeguarding the project’s smooth progress with strong supply capacity.

Moving forward, State Grid Ningxia Electric Power Co., Ltd. Material Company will continue to refine its material support services, further enhance its overall material support capacity and collaborative service level, and deliver more professional, efficient and reliable supply services to contribute solid material support to the high-quality development of the power grid.

QINGDAO, China, May 20, 2026 /PRNewswire/ — Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has released its 2025 Sustainability Report, providing a comprehensive overview of the company’s measurable progress achieved in environmental, social, and governance with dedication to safer, greener, and more inclusive, accessible healthcare and life sciences worldwide.

Within its LIFE sustainability framework of Leadership, Integrity, Future, and Ecosystem, Haier Biomedical actively supports and implements all 17 United Nations Sustainable Development Goals (SDGs). Through continuous technological innovation and locally integrated strategies in global markets, the company empowers public health initiatives worldwide with key focuses of strengthening localized service networks, advancing cutting-edge scientific research, and driving sustainable development across industrial chains with innovative low-carbon solutions.

“In 2025, we achieved three strategic leaps: from products to scenarios, from China to the world, and from a single industry to a platform ecosystem. Guided by our philosophy of ‘Intelligent of Life Science,’ Haier Biomedical continues to deepen green, low‑carbon innovation and global health accessibility under our core ‘LIFE’ framework,” said Tan Lixia, Chairwoman of Haier Biomedical.

Haier Biomedical remains committed to making R&D and innovation a strategic priority. It has established a clear three-tier R&D management structure that balances resource allocation, drives technological breakthroughs, and accelerates new product development. Guided by the dual engines of core technology advancement and deep user insight, the company ensures strategic alignment through mechanisms such as milestone reviews by the management committee, monthly progress reports, and weekly operational meetings. This approach has yielded strong results:

• R&D personnel account for 28.56% of the workforce, with total R&D investment reaching 323 million yuan (USD 47.25 million);
• New invention patents grew 50% year-on-year, and non-storage patents now represent 73% of the portfolio;
• It holds 428 software copyrights and has accumulated 51 provincial or higher-level science and technology awards, as well as involvement in setting 75 national, industry, group, and technical standards;
• Owns 34 technologies recognized as internationally leading and a track record of 0.70 patents and 0.18 software copyrights per million yuan in revenue.

Haier Biomedical is integrating AI into product R&D, launching “AI+” solutions that address key safety and efficient pain points in healthcare:

• The “AI+” Safety Cabinet, trained on over 7,000 annotated medicine vial images, achieves 99% recognition accuracy, covering 101 common vial types and significantly reducing medication errors.
• The Cytotoxic Drug Dispensing Robot with 3D-AI vision is developed for fully automated chemotherapy preparation, protecting healthcare workers from hazardous exposure.
• Its Fully Automated Cell Culture Workstation enables closed-loop cell processing from thawing to harvesting, improving standardization and traceability while reducing labor costs.

These innovations earned Haier Biomedical a second prize at the 2025 Qingdao Science and Technology Progress Award and first prize at the Shandong Provincial Science and Technology Progress Award.

In addition, Haier Biomedical has established a digitalized quality management process covering the entire journey from raw material intake to product dispatch, integrating digital capabilities into every aspect of production and quality control to drive smarter and more efficient quality management.

It has strengthened intelligent management and risk prevention through digitalization of the supply chain, quality and manufacturing. Its dual‑platform procurement system integrates supplier data and user feedback for real‑time quality optimization. Manufacturing digitalization enables full parameter monitoring, facial recognition for key processes, and real‑time SPC analytics. The digital quality platform makes quality visible, controllable, and assessable — reducing risks and ensuring product reliability.

Haier Biomedical’s smart IoT factory adopts automation, digitalization, and intelligent connectivity to precisely control production and dynamically monitor quality, effectively reducing in-process quality risks. The company is also building intelligent medical factories that integrate equipment, data, and controls to establish a full lifecycle production management model.

Driven by its vision to be “Making Life Better,” Haier Biomedical is dedicated to enhancing patient well‑being globally while making quality products accessible to more users. The company collaborates closely with international public welfare organizations, supporting communities through cash and product donations, totaling 1.406 million yuan (USD 205,697.8) during the reporting period.

Leveraging its technology and expertise, Haier Biomedical works with governments, NGOs, and universities to advance global health equity and make quality medical services more accessible. As a long‑term partner of GAVI, the company supports global immunization through its products. Since its inception in 2000, GAVI has served 1.2 billion children worldwide, significantly improving child health.

Haier Biomedical has made steady progress in its long‑term environmental investments, expanding its green product portfolio across energy saving, eco‑friendly materials, full lifecycle planning, and green packaging. The company has significantly reduced product energy consumption through innovations like Eco‑Drive technology and zero‑carbon solar direct‑drive cold storage.

During the reporting period, Haier Biomedical obtained 122 energy‑saving certificates covering 75 product models and added two new ENERGY STAR certified models, bringing the total to 34. The company has also partnered with institutions such as Eurofins, the University of Sheffield, and the University of Liverpool, providing low‑carbon equipment to support research while reducing environmental impact.

Furthermore, Haier Biomedical is committed to a diverse, equitable, and inclusive workplace and continuous talent development, with expanded dual career tracks for management and technical professionals. In late March 2026, following board and shareholder approval, the company established a compensation incentive fund to support equity incentives and employee stock ownership plans as part of its medium‑ to long‑term incentive programs.

Looking ahead, Haier Biomedical will continue its digital, global, and platform-driven transformation to build a world-leading integrated life science tools and intelligent productivity platform.

For more information, please visit: https://www.haiermedical.com/.

SINGAPORE, May 20, 2026 /PRNewswire/ — Bizcap, one of the fastest-growing alternative lenders globally, is marking one year of operations in Singapore by increasing its lending limit to $1 million, giving more SMEs fast access to larger, flexible funding solutions.

The announcement reflects Bizcap’s strong growth in the Singapore market since launching in early 2025, as well as increasing demand from local businesses and brokers for faster and more responsive funding options.

Bizcap Singapore has rapidly established itself as a trusted alternative lender for SMEs seeking a more flexible approach than traditional finance providers.

“When we launched, we had a vision to become Singapore’s most open-minded lender and I truly believe we’ve brought that vision to life over the past year,” said Joseph Lim, Bizcap’s Managing Partner for Asia.

“Over the last 12 months, we’ve seen strong momentum in the Singapore market as more SMEs and brokers look for funding partners that can move quickly and provide solutions tailored to their business needs.

“Increasing our lending limit to $1 million is a reflection of Bizcap’s growing presence in Singapore and our ability to support businesses with larger funding requirements while maintaining the speed and responsiveness we are known for.”

Over the past year, Bizcap Singapore has achieved several key milestones:

• Launched four new funding products: Line of Credit, Line of Credit Ultra, Prime Loan and Caveat Loan
• Facilitated more than $40 million in funding for Singapore SMEs
• Maintained its industry-leading speed, delivering approvals in principle within three hours
• Built a strong network of more than 300 partners
• Expanded its local team from one to seven employees.

Bizcap recently hosted a partner event in Singapore attended by more than 150 key partners to celebrate its one-year milestone. During the event, the company shared updates on its expanded $1 million lending limit, its broader growth ambitions across Asia, and the launch of its Bizcap Frequent Funders (BFF) program — a new loyalty initiative designed to reward partners with tiered incentives as they reach funding milestones.

As part of the celebrations, Bizcap also recognised a number of high-performing partners who achieved Platinum Partner status in 2025, acknowledging their ongoing support and contribution to the company’s growth in Singapore.

Bizcap has also strengthened its leadership team in Singapore with the promotion of Gareth Tan to General Manager, reinforcing the company’s commitment to continued growth in the local market.

Tony Truong, Bizcap’s Chief Credit Officer (APAC), said the increased lending limit would help make funding more accessible for Singapore SMEs looking to scale operations, improve cash flow or invest in future growth.

“At Bizcap, we are focused on making funding more accessible to Singapore SMEs by providing fast and flexible finance solutions that support real business outcomes,” said Truong.

“By lifting our lending limit to $1 million, we can now support larger deal sizes and help more businesses access the capital they require through flexible facility structures to help stabilise cash flow, invest in expansion, and manage unpredictable market dynamics.”

Bizcap’s Global Co-Founder and Co-CEO Zalman Blachman said the Singapore business had exceeded expectations in its first year of operation.

“To see the Singapore business grow from a standing start to such a strong position in just one year is a testament to the team on the ground and the demand for a more flexible approach to lending,” said Blachman.

Looking ahead, Bizcap Singapore is targeting more than $100 million in funding facilitated over the next 12 months as it continues to scale its presence in the local market.

“We’re just getting started,” Lim said. “The response from the Singapore market over the past year has been incredibly encouraging, and increasing our lending limit to $1 million is another important step in supporting SMEs with the fast, flexible funding they need to grow.”